We are honored to join American Academy of Neurology at #AAN2024 to present new data on Huntington's disease (HD). Read about the data here: bit.ly/3UkdkSn

#News: A #biosimilar was approved by the FDA today for #psoriaticarthritis and #plaquepsoriasis. We'reproud to continue providing access to treatments for patients living with inflammatory conditions in partnership with Alvotech. ow.ly/fAjA50RhGs2

On Wednesday, May 8, tune in to our live Q1 2024 earnings call with CEO Richard Francis and the Teva leadership team. Save the date: bit.ly/3JDSibf #QuarterlyResults #Q1Results #Earnings $Teva

#NEWS: New Phase 3 efficacy data from our SOLARIS trial show the potential of a long-acting treatment for #schizophrenia. Learn more here: ow.ly/hi2K50RzhMm

Teva Pharma Shoots To 5-Year High With Good News For Its Blockbuster Hopeful investors.com/news/technolog…

#NEWS: The US FDA has approved a new treatment associated with #tardivedyskinesia (TD) and #Huntingtonsdisease (HD) chorea for adults. Read more: ow.ly/3gKv50S1itH #TevaUSA

#NEWS: At #PsychCongressElevate2024, we presented results from the IMPACT-TD study. The registry and study evaluate the holistic effects of tardive dyskinesia along with real-world treatment outcomes. Learn more here: ow.ly/Y4th50S5EkW

#NEWS: New data on #schizophrenia treatment with long-acting injectables presented at #PsychCongressElevate2024, underscoring our commitment to meeting the needs of patients. Lean more here: ow.ly/faOW50S5ElF

#NEWS Teva launches the first generic GLP-1 in the U.S., indicated to treat patients with #type2diabetes mellitus. This provides an important & in demand treatment option for patients, reinforcing Teva as a generics powerhouse. ow.ly/Qpyy50SoxEV #TD2 #TevaUSA

We’re thrilled to be named on TIME's inaugural World’s Most Sustainable Companies of 2024. Teva is committed to a Healthy Future, with sustainability central to our business as we provide medicines to millions of patients around the world each day. ow.ly/cE7z50SsIqM

Partnering for better health with @Sanofi to bring much-needed innovations in treatment options for patients with #IBD, today we are announcing an update and accelerated timeline for our anti-tl1a Phase 2b clinical trial. Read more here: ow.ly/H9rP50SJOgA

Yesterday Teva CEO Richard Francis talked with Money Movers about our strong momentum, Q2 business performance and the progress on our #PivotToGrowth strategy. Watch the full interview here: lnkd.in/e_YH4A8y View highlights below: